Zevra Therapeutics, Inc. (ZVRA): Cost of Revenue

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2022-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

Older than the company's other figures. The latest Cost of Revenue is for the year ended 2023-12-31, while the company's latest annual report covers the year ended 2025-12-31. Its later filings do not report this line under the concept TickerFacts maps.

$2.94M
Year ended 2023-12-31
2021-12-31: $2.06M2022-12-31: $222.0K2023-12-31: $2.94M$2.94M
2021-12-31 Cost of Revenue (USD) 2023-12-31
Period endedCost of RevenueChange YoYSource filing
2023-12-31$2.94Mn/m2024-04-01, From 2023-01-01
2022-12-31$222.0Kn/c2024-04-01, From 2022-01-01
2021-12-31$2.06Mn/a2023-03-07, From 2021-01-01